What was XWEL’s net loss and loss per share for Q1 2026?

XWEL reported a net loss attributable to the company of $11,202 thousand for Q1 2026, compared with $4,719 thousand in Q1 2025. Net loss attributable to common stockholders was $11,178 thousand , resulting in a basic and diluted loss per share of $1.51 .

XWELL (XWEL) boosts liquidity with Series H financing despite wider Q1 2026 loss

Q: How did XWEL’s revenue change in the quarter ended March 31, 2026?

XWEL’s revenue for the quarter was $6,638 thousand , down slightly from $7,023 thousand a year earlier. The decline reflects lower contributions from certain operations, including the absence of HyperPointe revenues and reduced surge billing in the XpresTest segment.

Q: How much cash and working capital did XWEL have as of March 31, 2026?

As of March 31, 2026, XWEL held $16,800 thousand in cash and cash equivalents and $7 thousand in marketable securities. Total current assets were $19,747 thousand and current liabilities were $8,389 thousand , producing a working capital surplus of $11,358 thousand .

Q: What are the key terms of XWEL’s February 2026 Series H Preferred Stock financing?

In February 2026, XWEL issued 31,333 shares of Series H Convertible Preferred Stock at $1,000 stated value each, initially convertible into up to 66,665,957 common shares at $0.47 per share, plus Series H warrants for 66,665,957 shares at a $0.345 exercise price.

Q: What segments contribute to XWEL’s revenue and operating results?

XWEL operates three reportable segments: XpresSpa , XpresTest , and Naples Wax Center . For Q1 2026, segment operating income (loss) was $(592) thousand for XpresSpa, $1,067 thousand for XpresTest, $48 thousand for Naples Wax, and $(5,937) thousand for Corporate and other.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

10-Q

Rhea-AI Filing Summary

XWELL, Inc. reported a larger loss in the three months ended March 31, 2026 while materially improving its liquidity through new financing and liability reductions. Revenue was $6,638 thousand versus $7,023 thousand a year earlier, mainly from its XpresSpa, XpresTest and Naples Wax Center segments.

Net loss attributable to XWELL, Inc. was $11,202 thousand, compared with $4,719 thousand in the prior-year quarter, as higher general and administrative expenses and a $5,584 thousand loss from changes in derivative fair value weighed on results. Cash and cash equivalents rose to $16,800 thousand from $2,617 thousand after a February 2026 private placement of Series H Convertible Preferred Stock and warrants that generated net proceeds of $28,269 thousand.

The company used about $9,000 thousand of these proceeds to repurchase Series G preferred stock, convertible notes and warrants, simplifying its capital structure. Working capital swung to a surplus of $11,358 thousand from a deficit of $6,982 thousand, and management states it believes current cash and expected operating cash flows are sufficient to fund operations for at least the next twelve months.

Insights

Quarter shows deeper losses but a much stronger balance sheet from new preferred equity and debt cleanup.

XWELL posted Q1 2026 revenue of $6,638k, down modestly from $7,023k, but net loss widened to $11,202k from $4,719k, largely due to higher general and administrative costs and a $5,584k change in derivative fair value tied to prior financing structures.

Liquidity improved sharply: cash and cash equivalents increased to $16,800k, and working capital moved to an $11,358k surplus from a deficit. This came from a February 2026 private placement of Series H Convertible Preferred Stock and warrants, raising net proceeds of $28,269k, partly offset by $9,000k used to repurchase Series G preferred shares, convertible notes and warrants.

These transactions removed a derivative liability of $3,870k as of December 31, 2025 and extinguished related notes and preferred stock, leaving Series H as permanent equity with embedded conversion and warrant overhang. Management concludes it has sufficient liquidity for at least the next twelve months; future filings will show whether operating losses narrow enough to rely less on external capital.

Key Figures

Revenue: $6,638k Revenue prior-year quarter: $7,023k Net loss attributable to XWELL, Inc.: $11,202k +5 more

8 metrics

Revenue $6,638k Three months ended March 31, 2026

Revenue prior-year quarter $7,023k Three months ended March 31, 2025

Net loss attributable to XWELL, Inc. $11,202k Three months ended March 31, 2026

Cash and cash equivalents $16,800k As of March 31, 2026

Net proceeds from February 2026 Private Placement $28,269k Series H Preferred Stock and warrants financing

Repurchase of preferred stock, notes and warrants $9,000k Cash used in financing activities Q1 2026

Working capital $11,358k surplus As of March 31, 2026

Net cash used in operating activities $4,602k Three months ended March 31, 2026

Key Terms

Series H Convertible Preferred Stock, bifurcated embedded derivative, going concern, fair value hierarchy, +2 more

6 terms

Series H Convertible Preferred Stock financial

"31,333 shares of the Company’s newly-designated Series H Convertible Preferred Stock, par value of $0.01 per share"

bifurcated embedded derivative financial

"the fair value of the bifurcated embedded derivative related to the convertible preferred stock and Note was estimated using a Monte Carlo simulation model"

going concern financial

"financial statements have been prepared assuming that the Company will continue as a going concern"

A going concern is a business that is expected to continue its operations and meet its obligations for the foreseeable future, rather than shutting down or selling off assets. This assumption matters to investors because it indicates stability and ongoing profitability, making the business a more reliable investment. Think of it as believing a restaurant will stay open and serve customers, rather than closing down suddenly.

fair value hierarchy financial

"A fair value hierarchy exists, which requires an entity to maximize the use of observable inputs"

stock-based compensation financial

"Total stock-based compensation for the three months ended March 31, 2026 and 2025 was $886 and $83, respectively"

Stock-based compensation is when a company pays employees, directors or consultants with shares or the right to buy shares instead of or in addition to cash. It matters to investors because issuing stock or options spreads ownership thinner (like cutting a pie into more slices), which can reduce each existing share’s claim on profits and can also change reported earnings; investors watch it to assess true cost of running the business and how management is incentivized.

Registration Rights Agreement financial

"entered into a registration rights agreement (the “Registration Rights Agreement”) with the February 2026 Purchaser and the Placement Agent"

A registration rights agreement is a contract that gives investors the option to have their ownership stakes officially registered with the government, making it easier to sell their shares later. This agreement matters because it provides investors with a clearer path to cash out their investments if they choose, offering more liquidity and confidence in their ability to sell their holdings when desired.

10-Q Quarterly Reports: What Changes Quarter to Quarter →

05/20/2026 - 04:05 PM

0001410428--12-312026Q1falsehttp://fasb.org/us-gaap/2024#EmbeddedDerivativeGainLossOnEmbeddedDerivativeNetP5Y0001410428xwel:SeriesGConvertiblePreferredStockMemberus-gaap:PreferredStockMember2026-01-012026-03-310001410428xwel:SeriesGConvertiblePreferredStockMember2026-03-310001410428xwel:AmendedAndRestatedWarrantsMember2026-03-310001410428us-gaap:ConvertibleDebtMember2026-03-310001410428xwel:SeriesGConvertiblePreferredStockMember2026-03-020001410428xwel:AmendedAndRestatedWarrantsMember2026-03-020001410428us-gaap:ConvertibleDebtMember2026-03-020001410428us-gaap:ConvertibleDebtMember2026-03-020001410428xwel:ConcentricByGinkgoBioworksMember2026-01-012026-03-310001410428xwel:February2026PrivatePlacementMember2026-01-270001410428xwel:NaplesWaxLlcMember2026-01-012026-03-310001410428xwel:SeriesHWarrantsMember2026-02-242026-02-240001410428xwel:SeriesHConvertiblePreferredStockMember2026-02-242026-02-240001410428xwel:SeriesHWarrantsMember2026-02-240001410428xwel:SeriesHConvertiblePreferredStockMember2026-02-2400014104282025-05-162025-05-160001410428xwel:XwelInvIMember2026-01-012026-01-010001410428xwel:SeriesHWarrantsMemberxwel:PrivatePlacementTrancheTwoMember2026-03-032026-03-030001410428xwel:SeriesHWarrantsMemberxwel:PrivatePlacementTrancheOneMember2026-01-272026-01-270001410428xwel:SeriesHWarrantsMemberxwel:February2026PrivatePlacementMember2026-02-240001410428xwel:PlacementAgentWarrantsMember2026-02-240001410428xwel:SeriesHPlacementAgentWarrantsMemberus-gaap:MeasurementInputSharePriceMemberxwel:PrivatePlacementTrancheTwoMember2026-02-240001410428xwel:SeriesHPlacementAgentWarrantsMemberus-gaap:MeasurementInputSharePriceMemberxwel:PrivatePlacementTrancheOneMember2026-02-240001410428xwel:SeriesHPlacementAgentWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMemberxwel:PrivatePlacementTrancheTwoMember2026-02-240001410428xwel:SeriesHPlacementAgentWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMemberxwel:PrivatePlacementTrancheOneMember2026-02-240001410428xwel:SeriesHPlacementAgentWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMemberxwel:PrivatePlacementTrancheTwoMember2026-02-240001410428xwel:SeriesHPlacementAgentWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMemberxwel:PrivatePlacementTrancheOneMember2026-02-240001410428xwel:SeriesHPlacementAgentWarrantsMemberus-gaap:MeasurementInputExpectedTermMemberxwel:PrivatePlacementTrancheTwoMember2026-02-240001410428xwel:SeriesHPlacementAgentWarrantsMemberus-gaap:MeasurementInputExpectedTermMemberxwel:PrivatePlacementTrancheOneMember2026-02-240001410428xwel:SeriesHConvertiblePreferredStockMemberus-gaap:PreferredStockMember2026-03-310001410428xwel:SeriesGConvertiblePreferredStockMember2026-03-040001410428xwel:SeriesGConvertiblePreferredStockMemberus-gaap:PreferredStockMember2025-12-310001410428xwel:SeriesGConvertiblePreferredStockMemberus-gaap:PreferredStockMember2025-03-310001410428xwel:SeriesGConvertiblePreferredStockMemberus-gaap:PreferredStockMember2025-01-012025-03-310001410428xwel:SeriesHConvertiblePreferredStockMemberus-gaap:PreferredStockMember2026-01-012026-03-310001410428us-gaap:CommonStockMember2026-01-012026-03-310001410428us-gaap:RetainedEarningsMember2026-03-310001410428us-gaap:ParentMember2026-03-310001410428us-gaap:NoncontrollingInterestMember2026-03-310001410428us-gaap:AdditionalPaidInCapitalMember2026-03-310001410428us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-310001410428us-gaap:RetainedEarningsMember2025-12-310001410428us-gaap:ParentMember2025-12-310001410428us-gaap:NoncontrollingInterestMember2025-12-310001410428us-gaap:AdditionalPaidInCapitalMember2025-12-310001410428us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310001410428us-gaap:RetainedEarningsMember2025-03-310001410428us-gaap:ParentMember2025-03-310001410428us-gaap:NoncontrollingInterestMember2025-03-310001410428us-gaap:AdditionalPaidInCapitalMember2025-03-310001410428us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-310001410428us-gaap:RetainedEarningsMember2024-12-310001410428us-gaap:ParentMember2024-12-310001410428us-gaap:NoncontrollingInterestMember2024-12-310001410428us-gaap:AdditionalPaidInCapitalMember2024-12-310001410428us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001410428us-gaap:CommonStockMember2026-03-310001410428us-gaap:CommonStockMember2025-12-310001410428us-gaap:CommonStockMember2025-03-310001410428us-gaap:CommonStockMember2024-12-310001410428us-gaap:RestrictedStockUnitsRSUMember2026-03-310001410428us-gaap:RestrictedStockUnitsRSUMember2025-12-310001410428us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001410428xwel:NonVestedStockOptionsMember2026-01-012026-03-310001410428us-gaap:NonUsMember2026-01-012026-03-310001410428country:US2026-01-012026-03-310001410428us-gaap:NonUsMember2025-01-012025-03-310001410428country:US2025-01-012025-03-310001410428us-gaap:TransferredOverTimeMember2026-01-012026-03-310001410428us-gaap:TransferredAtPointInTimeMember2026-01-012026-03-310001410428us-gaap:ServiceMember2026-01-012026-03-310001410428us-gaap:ProductMember2026-01-012026-03-310001410428us-gaap:TransferredOverTimeMember2025-01-012025-03-310001410428us-gaap:TransferredAtPointInTimeMember2025-01-012025-03-310001410428us-gaap:ServiceMember2025-01-012025-03-310001410428us-gaap:ProductMember2025-01-012025-03-310001410428srt:MinimumMemberus-gaap:LeaseholdImprovementsMember2026-03-310001410428srt:MinimumMemberus-gaap:FurnitureAndFixturesMember2026-03-310001410428srt:MaximumMemberxwel:OtherOperatingEquipmentMember2026-03-310001410428srt:MaximumMemberus-gaap:LeaseholdImprovementsMember2026-03-310001410428srt:MaximumMemberus-gaap:FurnitureAndFixturesMember2026-03-310001410428srt:MinimumMemberus-gaap:LeaseholdImprovementsMember2025-12-310001410428srt:MinimumMemberus-gaap:FurnitureAndFixturesMember2025-12-310001410428srt:MaximumMemberxwel:OtherOperatingEquipmentMember2025-12-310001410428srt:MaximumMemberus-gaap:LeaseholdImprovementsMember2025-12-310001410428srt:MaximumMemberus-gaap:FurnitureAndFixturesMember2025-12-310001410428xwel:OtherOperatingEquipmentMember2026-03-310001410428us-gaap:LeaseholdImprovementsMember2026-03-310001410428us-gaap:FurnitureAndFixturesMember2026-03-310001410428xwel:OtherOperatingEquipmentMember2025-12-310001410428us-gaap:LeaseholdImprovementsMember2025-12-310001410428us-gaap:FurnitureAndFixturesMember2025-12-310001410428us-gaap:RetainedEarningsMember2026-01-012026-03-310001410428us-gaap:RetainedEarningsMember2025-01-012025-03-310001410428xwel:SeriesHConvertiblePreferredStockMemberxwel:February2026PrivatePlacementMember2026-02-242026-02-240001410428xwel:SeriesHConvertiblePreferredStockMemberxwel:February2026PrivatePlacementMember2026-02-012026-02-280001410428xwel:XwelInvIMember2025-03-310001410428xwel:SeriesHConvertiblePreferredStockMemberxwel:PrivatePlacementTrancheTwoMember2026-03-030001410428xwel:SeriesHConvertiblePreferredStockMemberxwel:PrivatePlacementTrancheOneMember2026-01-270001410428xwel:SeriesHConvertiblePreferredStockMemberus-gaap:PrivatePlacementMember2026-02-240001410428xwel:SeriesHPlacementAgentWarrantsMemberxwel:February2026PrivatePlacementMember2026-02-242026-02-240001410428xwel:PrivatePlacementTrancheTwoMember2026-02-242026-02-240001410428xwel:PrivatePlacementTrancheOneMember2026-02-242026-02-240001410428xwel:February2026PrivatePlacementMember2026-02-242026-02-240001410428xwel:SeriesWarrantsAndSeriesBWarrantsMember2026-02-242026-02-240001410428xwel:SeriesHConvertiblePreferredStockMemberxwel:February2026PrivatePlacementMember2026-01-012026-03-310001410428us-gaap:NoncontrollingInterestMember2026-01-012026-03-310001410428us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-310001410428us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-310001410428xwel:XprestestMember2026-01-012026-03-310001410428us-gaap:NonUsMember2026-03-310001410428country:US2026-03-310001410428us-gaap:NonUsMember2025-03-310001410428country:US2025-03-310001410428xwel:XwelInvIMember2025-01-012025-03-310001410428us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsNonrecurringMember2025-12-310001410428us-gaap:FairValueMeasurementsNonrecurringMember2025-12-310001410428us-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-310001410428us-gaap:EmbeddedDerivativeFinancialInstrumentsMemberus-gaap:FairValueMeasurementsRecurringMember2026-01-012026-03-310001410428us-gaap:EmbeddedDerivativeFinancialInstrumentsMember2026-01-012026-03-310001410428us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberxwel:Route1IncMember2026-03-310001410428us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberxwel:MarketableSecuritiesMember2026-03-310001410428us-gaap:FairValueMeasurementsRecurringMemberxwel:Route1IncMember2026-03-310001410428us-gaap:FairValueMeasurementsRecurringMemberxwel:MarketableSecuritiesMember2026-03-310001410428us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-310001410428us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-310001410428us-gaap:FairValueMeasurementsRecurringMember2026-03-310001410428us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberxwel:Route1IncMember2025-12-310001410428us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberxwel:MarketableSecuritiesMember2025-12-310001410428us-gaap:FairValueMeasurementsRecurringMemberxwel:Route1IncMember2025-12-310001410428us-gaap:FairValueMeasurementsRecurringMemberxwel:MarketableSecuritiesMember2025-12-310001410428us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-310001410428us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-310001410428xwel:NonVestedStockOptionsMember2026-03-310001410428xwel:NonVestedRSUsMember2026-03-310001410428us-gaap:ConvertibleDebtMember2026-01-012026-03-310001410428xwel:MeasurementInputPenaltyDividendRateMemberxwel:SeriesGConvertiblePreferredStockMember2026-03-020001410428us-gaap:MeasurementInputSharePriceMemberxwel:SeriesGConvertiblePreferredStockMember2026-03-020001410428us-gaap:MeasurementInputRiskFreeInterestRateMemberxwel:SeriesGConvertiblePreferredStockMember2026-03-020001410428us-gaap:MeasurementInputPriceVolatilityMemberxwel:SeriesGConvertiblePreferredStockMember2026-03-020001410428us-gaap:MeasurementInputExpectedTermMemberxwel:SeriesGConvertiblePreferredStockMember2026-03-020001410428us-gaap:MeasurementInputExpectedDividendRateMemberxwel:SeriesGConvertiblePreferredStockMember2026-03-020001410428us-gaap:MeasurementInputDiscountRateMemberxwel:SeriesGConvertiblePreferredStockMember2026-03-020001410428us-gaap:MeasurementInputDefaultRateMemberxwel:SeriesGConvertiblePreferredStockMember2026-03-020001410428us-gaap:MeasurementInputSharePriceMember2026-03-020001410428us-gaap:MeasurementInputRiskFreeInterestRateMember2026-03-020001410428us-gaap:MeasurementInputPriceVolatilityMember2026-03-020001410428us-gaap:MeasurementInputExpectedTermMember2026-03-020001410428us-gaap:MeasurementInputDiscountRateMember2026-03-020001410428us-gaap:MeasurementInputDefaultRateMember2026-03-020001410428xwel:SeriesGConvertiblePreferredStockMember2026-01-012026-03-310001410428xwel:SeriesGConvertiblePreferredStockMember2026-03-0200014104282026-03-020001410428us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EmbeddedDerivativeFinancialInstrumentsMember2025-12-310001410428us-gaap:FairValueMeasurementsRecurringMemberus-gaap:EmbeddedDerivativeFinancialInstrumentsMember2025-12-310001410428us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-310001410428us-gaap:FairValueMeasurementsRecurringMember2025-12-310001410428xwel:SeriesGConvertiblePreferredStockMember2026-02-240001410428xwel:XpresspaMember2026-01-012026-03-310001410428xwel:NaplesWaxMember2026-01-012026-03-310001410428us-gaap:CorporateAndOtherMember2026-01-012026-03-310001410428xwel:XprestestMember2025-01-012025-03-310001410428xwel:XpresspaMember2025-01-012025-03-310001410428xwel:NaplesWaxMember2025-01-012025-03-310001410428us-gaap:CorporateAndOtherMember2025-01-012025-03-310001410428xwel:NaplesWaxLlcMember2026-03-310001410428xwel:NaplesWaxLlcMember2025-12-310001410428us-gaap:ConvertibleDebtMember2026-01-012026-03-310001410428us-gaap:ConvertibleDebtMember2026-03-310001410428xwel:ProductAndServiceMemberxwel:XpresspaMember2026-01-012026-03-310001410428xwel:ProductAndServiceMemberxwel:NaplesWaxMember2026-01-012026-03-310001410428xwel:LaborMemberxwel:XprestestMember2026-01-012026-03-310001410428xwel:LaborMemberxwel:XpresspaMember2026-01-012026-03-310001410428xwel:LaborMemberxwel:NaplesWaxMember2026-01-012026-03-310001410428xwel:ProductAndServiceMember2026-01-012026-03-310001410428xwel:LaborMember2026-01-012026-03-310001410428xwel:ProductAndServiceMemberxwel:XpresspaMember2025-01-012025-03-310001410428xwel:ProductAndServiceMemberxwel:NaplesWaxMember2025-01-012025-03-310001410428xwel:LaborMemberxwel:XprestestMember2025-01-012025-03-310001410428xwel:LaborMemberxwel:XpresspaMember2025-01-012025-03-310001410428xwel:LaborMemberxwel:NaplesWaxMember2025-01-012025-03-310001410428xwel:ProductAndServiceMember2025-01-012025-03-310001410428xwel:LaborMember2025-01-012025-03-3100014104282025-01-012025-12-3100014104282025-05-160001410428xwel:SeriesHPlacementAgentWarrantsMember2026-02-2400014104282026-02-240001410428xwel:SeriesHConvertiblePreferredStockMemberxwel:February2026PrivatePlacementMember2026-02-2400014104282025-03-3100014104282024-12-310001410428xwel:XprestestMember2026-03-310001410428xwel:XpresspaMember2026-03-310001410428xwel:NaplesWaxMember2026-03-310001410428us-gaap:CorporateAndOtherMember2026-03-310001410428xwel:XprestestMember2025-12-310001410428xwel:XpresspaMember2025-12-310001410428xwel:NaplesWaxMember2025-12-310001410428us-gaap:CorporateAndOtherMember2025-12-310001410428xwel:SeriesHConvertiblePreferredStockMember2026-01-012026-03-310001410428us-gaap:WarrantMember2026-01-012026-03-310001410428us-gaap:RestrictedStockUnitsRSUMember2026-01-012026-03-310001410428us-gaap:EmployeeStockOptionMember2026-01-012026-03-310001410428xwel:SeriesGConvertiblePreferredStockMember2025-01-012025-03-310001410428us-gaap:WarrantMember2025-01-012025-03-310001410428us-gaap:EmployeeStockOptionMember2025-01-012025-03-310001410428us-gaap:NoncontrollingInterestMember2025-01-012025-03-310001410428us-gaap:ParentMember2026-01-012026-03-310001410428us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-310001410428us-gaap:ParentMember2025-01-012025-03-310001410428us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-3100014104282025-01-012025-03-310001410428xwel:XwelInvIMember2025-12-150001410428xwel:XwelInvIMember2025-05-1200014104282026-03-3100014104282025-12-3100014104282026-05-1400014104282026-01-012026-03-31xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:purexwel:Yxwel:segmentxwel:locationxwel:tranche

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2026

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___ to ___

Commission file number: 001-34785

XWELL, Inc.

(Exact Name of Registrant as Specified in its Charter)


Delaware		20-4988129
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

254 West 31^st Street, 11th Floor, New York, NY		10001
(Address of principal executive offices)		(Zip Code)

(Registrant’s Telephone Number, Including Area Code): (212) 750-9595

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.01 per share		XWEL		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of May 14, 2026, 8,444,266 shares of the registrant’s common stock were outstanding.

Table of Contents

XWELL, Inc. and Subsidiaries

Table of Contents

		Page
PART I. FINANCIAL INFORMATION		3

Item 1.	Condensed Consolidated Financial Statements (Unaudited)	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	24
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	31
Item 4.	Controls and Procedures	31

PART II. OTHER INFORMATION		33

Item 1.	Legal Proceedings	33
Item 1A.	Risk Factors	33
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	33
Item 3.	Defaults Upon Senior Securities	33
Item 4.	Mine Safety Disclosures	33
Item 5.	Other Information	33
Item 6.	Exhibits	34

Table of Contents

PART I - FINANCIAL INFORMATION

Item 1.Condensed Consolidated Financial Statements (Unaudited)

XWELL, Inc. and Subsidiaries

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

(In thousands, except share and per share data)


		March 31,			December 31,
		2026			2025
Current assets
Cash and cash equivalents		$	16,800		$	2,617
Marketable Securities			7			7
Accounts receivable			1,317			1,560
Inventory			453			509
Other current assets			1,170			1,217
Total current assets			19,747			5,910

Restricted cash			252			251
Property and equipment, net			1,773			1,665
Intangible assets, net			61			101
Operating lease right of use assets, net			954			1,039
Security deposits			2,104			2,127
Other assets			101			124
Total assets		$	24,992		$	11,217

Current liabilities
Accounts payable		$	3,535		$	2,836
Accrued expenses and other current liabilities			2,275			2,940
Accrued Series G Convertible Preferred payable			—			538
Current portion of operating lease liabilities			1,789			1,862
Deferred revenue			790			1,126
Convertible senior secured note, net			—			3,590
Total current liabilities			8,389			12,892

Long-term liabilities
Derivative liability			—			3,870
Operating lease liabilities			6,525			7,035
Total liabilities			14,914			23,797
Commitments and contingencies (see Note 8)
Temporary equity
Series G Convertible Preferred Stock, $0.01 par value per share and $1,000 stated value per share, 4,000 shares authorized; 0 and 196 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively; Liquidation preference of $0 as of March 31, 2026			—			224
Equity (Deficit)
Series H Convertible Preferred Stock, $0.01 par value per share and $1,000 stated value per share, 35,000 shares authorized; 31,333 and 0 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively; Liquidation preference of $31,333 as of March 31, 2026			—			—
Common Stock, $0.01 par value per share, 150,000,000 shares authorized; 7,926,766 and 6,071,324 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively			79			61
Additional paid-in capital			502,869			468,915
Accumulated deficit			(500,899)			(489,697)
Accumulated other comprehensive loss			(1,660)			(1,541)
Total equity (deficit) attributable to XWELL, Inc.			389			(22,262)
Noncontrolling interests			9,689			9,458
Total equity (deficit)			10,078			(12,804)
Total liabilities, temporary equity and equity		$	24,992		$	11,217

The accompanying notes form an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

XWELL, Inc. and Subsidiaries

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

(In thousands, except share and per share data)


		Three months ended March 31,
		2026			2025

Revenue, net
Services		$	6,064		$	6,420
Products			574			603
Total revenue, net			6,638			7,023

Cost of sales
Labor			2,974			3,967
Occupancy			761			1,134
Products and other operating costs			550			603
Total cost of sales			4,285			5,704
Gross Profit			2,353			1,319
Depreciation and amortization			172			166
General and administrative			7,595			4,311
Total operating expenses			7,767			4,477
Operating loss			(5,414)			(3,158)
Change in fair value of derivative liabilities			(5,584)			(142)
Change in fair value of warrant liability			—			2,590
Loss on issuance of Series G Preferred Stock			—			(3,443)
Interest (expense) income, net			(43)			58
Foreign exchange gain (loss)			77			(455)
Loss on investments, realized and unrealized			(22)			(5)
Other non-operating expense, net			(26)			(33)
Loss before income taxes			(11,012)			(4,588)
Income tax expense			—			—
Net loss			(11,012)			(4,588)
Net (income) attributable to noncontrolling interests			(190)			(131)
Net loss attributable to XWELL, Inc.		$	(11,202)		$	(4,719)
Net loss			(11,012)			(4,588)
Other comprehensive income (loss) from operations			(78)			189
Comprehensive loss		$	(11,090)		$	(4,399)
Loss per share
Preferred stock dividends			(82)			(68)
Preferred stock accretion			—			(499)
Deemed contribution on Repurchase of Series G Preferred Stock			106			—
Net loss attributable to XWELL, Inc. common stockholders		$	(11,178)		$	(5,286)
Basic and diluted loss per share		$	(1.51)		$	(1.00)
Weighted-average number of shares outstanding
Basic			7,396,148			5,261,024
Diluted			7,396,148			5,261,024

The accompanying notes form an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

XWELL, Inc. and Subsidiaries

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN TEMPORARY EQUITY AND STOCKHOLDERS’ EQUITY (DEFICIT)

(Unaudited)

(In thousands, except share and per share data)


																					Accumulated
		Series G Convertible				Series H Convertible									Additional						other			Total			Non-
		Preferred stock				Preferred stock					Common stock				paid-			Accumulated			comprehensive			Company			controlling			Total
		Shares		Amount		Shares		Amount			Shares		Amount		in capital			deficit			loss			equity			interests			equity (deficit)
January 1, 2026		196		$	224	—		$	—		6,071,324		$	61	$	468,915		$	(489,697)		$	(1,541)		$	(22,262)		$	9,458		$	(12,804)
Issuance of common stock for Series G preferred stock installment redemption		—			—	—			—		1,855,442			18		525			—			—			543			—			543
Stock-based compensation		—			—	—			—		—			—		886			—			—			886			—			886
Issuance of Series H Preferred Stock in private placement, net of transaction costs		—			—	31,333			—		—			—		28,269			—			—			28,269			—			28,269
Series G Preferred Stock dividends		—			—	—			—		—			—		(82)			—			—			(82)			—			(82)
Extinguishment of Series G Preferred Stock and convertible notes		(196)			(224)	—			—		—			—		4,356			—			—			4,356			—			4,356
Foreign currency translation		—			—	—			—		—			—		—			—			(141)			(141)			41			(100)
Other comprehensive income, net		—			—	—			—		—			—		—			—			22			22			—			22
Net loss for the period		—			—	—			—		—			—		—			(11,202)			—			(11,202)			190			(11,012)
March 31, 2026		—		$	—	31,333		$	—		7,926,766		$	79	$	502,869		$	(500,899)		$	(1,660)		$	389		$	9,689		$	10,078

The accompanying notes form an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

XWELL, Inc. and Subsidiaries

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN TEMPORARY EQUITY AND STOCKHOLDERS’ EQUITY (DEFICIT) (Continued)

(Unaudited)

(In thousands, except share and per share data)


																							Accumulated
		Series G Convertible									Additional						Additional						other
		Preferred stock					Common stock				paid-			Accumulated			comprehensive			Company			controlling			Total
		Shares		Amount			Shares		Amount		in capital			deficit			loss			equity			interests			equity
January 1, 2025		—		$	—		5,261,024		$	53	$	473,824		$	(472,706)		$	(1,959)		$	(788)		$	8,530		$	7,742
Stock-based compensation		—			—		—			—		80			—			—			80			3			83
Issuance of Series G Preferred Stock in private placement, net of transaction costs		4,000			—		—			—		—			—			—			—			—			—
Series G Preferred Stock accretion		—			499		—			—		(499)			—			—			(499)			—			(499)
Series G Preferred Stock dividends		—			68		—			—		(68)			—			—			(68)			—			(68)
Foreign currency translation		—					—			—		—			—			199			199			(10)			189
Net loss for the period		—			—		—			—		—			(4,719)			—			(4,719)			131			(4,588)
March 31, 2025		4,000		$	567		5,261,024		$	53	$	473,337		$	(477,425)		$	(1,760)		$	(5,795)		$	8,654		$	2,859

The accompanying notes form an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

XWELL, Inc. and Subsidiaries

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)


		Three months ended March 31,
		2026		2025
Cash flows from operating activities
Net loss		$	(11,012)	$	(4,588)
Adjustments to reconcile net loss to net cash used in operating activities:
Items included in net loss not affecting operating cash flows:
Depreciation and amortization			172		166
Unrealized gain on marketable securities			—		(24)
Foreign currency remeasurement (gain) loss			(77)		455
Gain on lease termination			—		(401)
Amortization of operating lease right of use asset			85		246
Provision for credit losses			(6)		6
Stock-based compensation			886		83
Non-cash interest expense			53
Gain on equity investment			23		29
Change in fair value of derivative liability			5,584		142
Change in fair value of warrant liability			—		(2,590)
Loss on issuance of Series G Preferred Stock			—		3,443
Changes in assets and liabilities:
(Increase) decrease in inventory			55		(31)
Decrease in accounts receivable			251		269
(Decrease) in deferred revenue			(336)		(58)
(Increase) decrease in other assets, current and non-current			14		(669)
(Decrease) in other liabilities, current and non-current			(1,166)		(1,255)
Increase in accounts payable			872		599
Net cash used in operating activities			(4,602)		(4,178)
Cash flows from investing activities
Acquisition of property and equipment			(390)		(424)
Investment in marketable securities			-		(46)
Net cash provided by (used in) investing activities			(390)		(470)
Cash flows from financing activities
Payment for Repurchase of preferred stock, convertible notes and warrants			(9,000)		—
Proceeds from registered offering, net of offering costs			28,269		3,745
Redemption of preferred stock			(76)		—
Net cash provided by financing activities			19,193		3,745
Effect of exchange rate changes on cash, cash equivalents and restricted cash			(24)		3
Increase (decrease) in cash, cash equivalents and restricted cash			14,177		(900)
Cash, cash equivalents, and restricted cash at beginning of the year			2,875		5,301
Cash, cash equivalents, and restricted cash at end of the period		$	17,052	$	4,401
Cash paid for
Income taxes		$	—	$	—
Non-cash investing and financing transactions
Capital expenditures included in Accounts payable, accrued expenses and other current liabilities			(151)		4
Accrual of Series G convertible preferred stock dividends			82		68
Accretion of Series G convertible preferred stock to redemption value			—		499
Initial fair value of warrant liability			—		5,873
Initial fair value of derivative liability			—		1,315
Noncash conversion of Series G convertible preferred stock			543		—
Deemed dividend on Repurchase of Series G Preferred Stock			106		—
Fair value of Placement Agent warrants			7,152		—
Contribution on Repurchase of related party debt, net of warrant repurchase cost			4,250		—

The accompanying notes form an integral part of these unaudited condensed consolidated financial statements.

Table of Contents

XWELL, Inc. and Subsidiaries

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

(In thousands, except for share and per share data)

Note 1. Business Overview and Going Concern

Overview

XWELL (“XWELL” or the “Company”) is a global wellness organization dedicated to delivering restorative and health-focused services to travelers through its three reportable operating segments: XpresSpa®, XpresTest®, and Naples Wax Center®. XpresSpa operates spa service locations in major airports, offering massage, skincare, and travel products. XpresTest transitioned from providing COVID-19 testing to supporting public health efforts through bio-surveillance programs at international airports. Naples Wax Center provides upscale hair removal and skincare services through its branded locations.

Liquidity Analysis

The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. While the Company has suffered recurring losses and negative cash flows from operations, management evaluated whether substantial doubt existed about the Company’s ability to continue as a going concern within one year after the date these unaudited condensed consolidated financial statements are issued.

The Company has significantly reduced operating and overhead expenses, while it continues to focus on returning to overall profitability. Management is implementing various strategic initiatives to reduce operating expenses, improve working capital and enhance cash flow. These include cost reduction efforts, capital spending controls, and financing options such as the February 2026 Private placement (referenced below).

The Company’s increase in liquidity during the period was primarily attributable to proceeds from a private placement of Series H Convertible Preferred Stock with accompanying warrants completed in February 2026 (the “February 2026 Private Placement”), which generated net proceeds of $28,269. During the three months ended March 31, 2026, the Company used approximately $9,000 of these proceeds to repurchase outstanding Series G Preferred Stock, certain convertible notes, and related warrants as part of a strategic effort to simplify its capital structure and reduce future financing obligations. The remaining proceeds were used to support general corporate purposes and working capital needs.

The Company continues to focus on managing operating expenses, optimizing working capital, and improving cash flows from operations. Based on its current cash position and expected operating cash flows, the Company believes it has sufficient liquidity to fund its operations and meet its obligations for at least the next twelve months.

Table of Contents

Note 2. Accounting and Reporting Policies

Basis of Presentation and Principles of Consolidation

The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Article 8-03 of Regulation S-X and should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as amended. The condensed consolidated balance sheet as of December 31, 2025 was derived from the audited annual financial statements but does not include all information required by GAAP for annual financial statements. The financial statements include the accounts of the Company, all entities that are wholly owned by the Company, and all entities in which the Company has a controlling financial interest. All adjustments that, in the opinion of management, are necessary for a fair presentation for the periods presented have been reflected by the Company. Such adjustments are of a normal, recurring nature. The results of operations for the three months ended March 31, 2026, are not necessarily indicative of the results that may be expected for the entire fiscal year or for any other interim period. All significant intercompany balances and transactions have been eliminated in consolidation.

Use of estimates

The preparation of the accompanying unaudited condensed consolidated financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses for the periods presented. Actual results may differ from such estimates. Significant items subject to such estimates and assumptions include the Company’s long-lived assets, the valuation of stock-based compensation, fair value of warrants, derivative liability, deferred tax assets and liabilities, income tax uncertainties, and other contingencies.

Note 3. Cash, Cash Equivalents, and Restricted Cash

A reconciliation of the Company’s cash and cash equivalents in the unaudited condensed consolidated balance sheets to cash, cash equivalents and restricted cash in the unaudited condensed consolidated statements of cash flows as of March 31, 2026, and December 31, 2025 is as follows:


		March 31, 2026			December 31, 2025
Cash denominated in United States dollars		$	15,402		$	1,100
Cash denominated in currency other than United States dollars			1,294			1,451
Restricted cash			252			251
Credit and debit card receivables			104			66
Total cash, cash equivalents and restricted cash		$	17,052		$	2,868

The Company places its cash and temporary cash investments with credit quality institutions. At times, such cash denominated in United States dollars may be in excess of the Federal Deposit Insurance Corporation (“FDIC”) insurance limit. If the Company were to distribute the amounts held overseas, the Company would need to follow an approval and distribution process as defined in its operating and partnership agreements, which may delay and/or reduce the availability of that cash to the Company.

Table of Contents

Note 4. Other current assets

As of March 31, 2026, and December 31, 2025, other current assets consisted of the following:


		March 31, 2026			December 31, 2025
Prepaid expenses		$	1,170		$	1,217
Total other current assets		$	1,170		$	1,217

Prepaid expenses are predominantly comprised of financed and prepaid insurance policies and IT hosting services, which have terms of one year or less.

Note 5. Property and Equipment, net

Property and equipment are comprised of the following:


		March 31,			December 31,
		2026			2025		Useful Life
Leasehold improvements		$	4,164		$	6,094	Average 5-8 years
Furniture and fixtures			317			468	3-4 years
Other operating equipment			897			1,028	Maximum 5 years
			5,378			7,590
Accumulated depreciation			(3,605)			(5,925)
Total property and equipment, net		$	1,773		$	1,665

Depreciation expense was $132 and $90 for the three months ended March 31, 2026 and 2025, respectively.

Note 6. Fair Value Measurements

Fair value is the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. A fair value hierarchy exists, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value are:

Level 1: Inputs are quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2: Pricing inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reported date.

Level 3: Unobservable inputs, that are supported by little or no market activity and are developed based on the best information available in the circumstances. For example, inputs derived through extrapolation or interpolation that cannot be corroborated by observable market data.

The following table presents the placement in the fair value hierarchy of the Company’s assets and liabilities measured at fair value on a recurring and nonrecurring basis as of March 31, 2026 and December 31, 2025. Assets and liabilities that are measured at fair value on a nonrecurring basis relate primarily to tangible property and equipment, right-of-use assets, and other intangible assets, which are remeasured when the derived fair value is below carrying value in the consolidated balance sheets. Recoverability is based on estimated undiscounted cash flows or other relevant observable/unobservable

Table of Contents

measures. For these assets, the Company does not periodically adjust carrying value to fair value except in the event of impairment. If it is determined that impairment has occurred, the carrying value of the asset is reduced to fair value and the difference is included in Impairment of long-lived assets and Impairment of operating lease right-of-use assets on the condensed consolidated statements of operations and comprehensive loss.

Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of and during the three months ended March 31, 2026. The carrying amounts of cash equivalents, accounts receivable, and accounts payable approximated their fair values as of March 31, 2026 due to their short-term nature. The fair value of the bifurcated embedded derivative related to the convertible preferred stock and Note was estimated using a Monte Carlo simulation model, which uses as inputs the fair value of our common stock and estimates for the equity volatility of our common stock, the time to maturity of the convertible preferred stock, the risk-free interest rate for a period that approximates the time to maturity, dividend rate, a penalty dividend rate, and our probability of default.


				Fair value measurement at reporting date using
				Quoted prices in
				active markets		Significant other		Significant
				for identical		observable		unobservable
		Balance		assets (Level 1)		inputs (Level 2)		inputs (Level 3)
As of March 31, 2026:
Recurring fair value measurements
Equity and debt securities:
Route1, Inc.		$	90	$	—	$	90	$	—
Marketable securities			7		7		—		—
Total equity and debt securities			97		7		90		—
Total recurring fair value measurements		$	97	$	7	$	90	$	—

As of December 31, 2025
Recurring fair value measurements
Equity and debt securities:
Route1		$	112	$	—	$	112	$	—
Marketable securities			7		7		—		—
Total equity and debt securities			119		7		112		—
Derivatives:
Derivative liability			3,870		—		—		3,870
Total derivatives			3,870		—		—		3,870
Total recurring fair value measurements		$	3,989	$	7	$	112	$	3,870
Nonrecurring fair value measurements
Property, plant and equipment		$	1,665	$	—	$	—	$	1,665
Operating lease right-of-use asset			1,039		—		—		1,039
Convertible senior secured note			6,689		—		—		6,689
Total nonrecurring fair value measurements		$	9,393	$	—	$	—	$	9,393

Table of Contents

The following table sets forth a summary of the change in the fair value of the bifurcated embedded derivative liabilities that are measured at fair value on a recurring basis:


Balance on January 1, 2026		3,870
Change in fair value of bifurcated embedded derivative		5,584
Extinguishment of convertible preferred stock with bifurcated embedded derivative		(9,454)
Balance on March 31, 2026	$	—

Note 7. Accrued expenses and other current liabilities

As of March 31, 2026, and December 31, 2025, accrued expenses and other current liabilities consisted of the following:



		March 31, 2026			December 31, 2025
Accrued compensation		$	1,144		$	905
Tax-related liabilities			499			527
Common area maintenance accruals			8			41
AP Accruals			107			78
Gift certificates			333			331
Other miscellaneous accruals			184			1,058
Total accrued expenses and other current liabilities		$	2,275		$	2,940

Note 8. Commitments and Contingencies

Certain of the Company’s outstanding legal matters include speculative claims for substantial or indeterminate amounts of damages. The Company regularly evaluates developments in its legal matters that could affect the amount of any potential liability and adjusts as appropriate. A significant judgment is required to determine both the likelihood of there being any potential liability and the estimated amount of a loss related to the Company’s legal matters.

With respect to the Company’s outstanding legal matters, based on its current knowledge, the Company’s management believes that the amount or range of a potential loss will not, either individually or in the aggregate, have a material adverse effect on its business, consolidated financial position, results of operations or cash flows. However, the outcome of such legal matters is inherently unpredictable and subject to significant uncertainties. The Company evaluated the outstanding legal matters and assessed the probability and likelihood of the occurrence of liability.

The Company expenses legal fees in the period in which they are incurred.

November 2025 Employment Litigation

In November 2025, a former employee initiated an employment-related legal proceeding against the Company, as previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025. During the three months ended March 31, 2026, the Company entered into a confidential settlement agreement to resolve the matter. The matter was settled for a de minimis amount, and the case has been dismissed with prejudice.

Table of Contents

XpresSpa Holdings, LLC (“XpresSpa”) v. Cordial Endeavor Concessions of Atlanta, LLC (“Cordial”), et al., Arbitration Case No. 2126399.

The Company’s subsidiary, XpressSpa Holdings, LLC, is party to an arbitration proceeding (the “Arbitration”) which was requested by the City of Atlanta relating to agreements by and between Cordial and XpresSpa for the operation of the XpresSpa locations in Hartsfield - Jackson Atlanta International Airport (“ATL”) in ATL Terminal A and ATL Terminal C. The City of Atlanta filed an application to compel arbitration in the Superior Court of Fulton County, and on November 5, 2024, the court granted that application and ordered the parties to arbitrate their disagreements.

This dispute arises out of alleged breaches of contract between the parties as well as other alleged improper conduct relating to the agreements. The arbitration hearing was completed in March 2026, and the parties are currently awaiting the arbitrator’s final decision.

Other Arrangements

On May 16, 2025, the Company entered into a sales and marketing agreement with a vendor that obligates the Company to make payments totaling $662 over the next three years. Payments are due quarterly, with the first installment beginning in July 2025.

In addition to those matters specifically set forth herein, the Company and its subsidiaries are involved in various other claims and legal actions that arise in the ordinary course of business. The Company does not believe that the ultimate resolution of these actions will have a material adverse effect on the Company’s financial position, results of operations, liquidity, or capital resources. However, a significant increase in the number of these claims, or one or more successful claims under which the Company incurs greater liabilities than the Company currently anticipates, could materially adversely affect the Company’s business, financial condition, results of operations and cash flows.

In the event that an action is brought against the Company or one of its subsidiaries, the Company will investigate the allegation and vigorously defend itself.

Note 9. Stockholders’ Equity and Warrants

February 2026 Private Placement

On February 24, 2026, the Company entered into the February 2026 Purchase Agreement with the a certain accredited investor (the “February 2026 Purchaser”) for the issuance and sale in a private placement of an aggregate of (i) 31,333 shares of the Company’s newly-designated Series H Convertible Preferred Stock, par value of $0.01 per share and a stated value of $1,000 per share (the “Series H Preferred Stock”), initially convertible into up to 66,665,957 shares of common stock (the “Series H Conversion Shares”), at an initial conversion price of $0.47 per share, subject to adjustment for certain customary adjustments, and (ii) the warrants (the “Series H Warrants”) to purchase up to 66,665,957 shares of common stock, at an initial exercise price of $0.345 per share, subject to adjustment for certain customary adjustments, for aggregate gross proceeds of approximately $31,300. The Series H Warrants expire three years from the date of issuance. The February 2026 Private Placement closed in two tranches, with 30,832 shares of Series H Preferred Stock and 65,600,000 Series H Warrants issued on February 27, 2026 (the “First Closing”), and 501 shares of Series H Preferred Stock and 1,065,957 Series H Warrants issued on March 3, 2026 (the “Second Closing”, and collectively with the First Closing, the “Closing”).

Table of Contents

aggregate number of shares of common stock underlying the securities issued in the February 2026 Private Placement, with terms identical to the Series H Warrants, except that the Series H Placement Agent Warrants have a term of five (5) years from the date of issuance. The Placement Agency Agreement contains customary representations, warranties and agreements of the parties, and customary indemnification obligations of the Company.

Series H Preferred Stock

The terms of the Series H Preferred Stock are set forth in the Series H Certificate of Designations. The shares of Series H Preferred Stock are convertible into the Series H Conversion Shares at the election of the holders of the Series H Preferred Stock (the “Holders”) at any time at an initial conversion price of $0.47 per share (the “Series H Conversion Price”). The Series H Conversion Price is subject to customary adjustments for stock dividends, stock splits, reclassifications, stock combinations and the like.

A Holder of the Series H Preferred Stock may not convert any portion of the Series H Preferred Stock to the extent that the Holder, together with its affiliates, would beneficially own more than 4.99% of the Company’s outstanding shares of Common Stock immediately after conversion, except that upon at least 61 days’ prior notice from the Holder to the Company, the Holder may increase the beneficial ownership limitation to up to 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the conversion.

Pursuant to the Series H Certificate of Designations, so long as any shares of the Series H Preferred Stock are outstanding, the Company may not, directly or indirectly, redeem, or declare or pay any cash dividend or distribution on, any securities of the Company without the prior express written consent of the Required Holders (as defined in the Series H Certificate of Designations). In the event that dividends are consented to by the Required Holders, the Holders of the Series H Preferred Stock shall be entitled to receive dividends on shares of the Series H Preferred Stock equal (on an as-if-converted-to-Common-Stock basis) to and in the same form as dividends actually paid on shares of the Common Stock when, as and if such dividends are paid on shares of the Common Stock. No other dividends may be paid on shares of the Series H Preferred Stock.

Except as otherwise provided in the Series H Certificate of Designations or as otherwise required by law, the Series H Preferred Stock will have no voting rights except as provided by law. However, as long as any shares of Series H Preferred Stock are outstanding, the Company may not, without the affirmative vote at a meeting duly called for such purpose, or the written consent without a meeting, of the Required Holders, voting together as a single class, (a) amend or repeal any provision of, or add any provision to, its charter documents, including, without limitation, its Certificate of Incorporation or bylaws, the Series H Certificate of Designation, or file any certificate of designations or articles of amendment of any series of shares of preferred stock, in each case, only if such action would adversely alter or change in any respect the preferences, rights, privileges or powers, or restrictions provided for the benefit, of the Series H Preferred Stock, regardless of whether any such action shall be by means of amendment to the Certificate of Incorporation or by merger, consolidation or otherwise; (b) increase or decrease (other than by conversion) the authorized number of shares of the Series H Preferred Stock; (c) create or authorize (by reclassification or otherwise) any new class or series of shares that has a preference over the Series H Preferred Stock with respect to dividends or the distribution of assets on the liquidation, dissolution or winding up of the Company; (d) pay dividends or make any other distribution on any shares of any capital stock of the Company junior in rank to the Series H Preferred Stock; or (e) whether or not prohibited by the terms of the Series H Preferred Stock, circumvent a right of the Series H Preferred Stock.

The Series H Preferred Shares are not mandatorily redeemable and do not embody an unconditional obligation to settle in a variable number of equity shares. As such, the Series H Preferred Stock are classified as permanent equity on the unaudited condensed consolidated balance sheets. The holder’s contingent redemption right in the event of certain deemed liquidation events does not preclude permanent equity classification. The Series H Preferred Shares were determined to be more akin to an equity-like host than a debt-like host for purposes of assessing embedded derivative features for potential bifurcation. The embedded conversion feature is considered to be clearly and closely related to the associated convertible preferred stock host instrument and therefore was not bifurcated from the equity host.

Table of Contents

Series H Warrants

The exercise price of the Series H Warrants is subject to customary adjustments for stock dividends, stock splits, reclassifications and the like. A holder of the Series H Warrants may not exercise any portion of such holder’s Warrants to the extent that the holder, together with its affiliates, would beneficially own more than 4.99% of the Company’s outstanding shares of Common Stock immediately after exercise, except that upon at least 61 days’ prior notice from the holder to the Company, the holder may increase the beneficial ownership limitation to up to 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the exercise.

The Company assessed the Series H Warrants under ASC 480 and ASC 815 and determined that they met the requirements to be classified in stockholders’ equity upon issuance.

Pursuant to the Placement Agency Agreement, the Company issued to the Placement Agent the Series H Placement Agent Warrants to purchase 5,333,277 shares of Common Stock with the same terms as the Series H Warrants except that the Series H Placement Agent Warrants have a term of five (5) years from the date of issuance. The Series H Placement Agent Warrants are within the scope of ASC 718 pursuant to ASC 718-10-20 and were determined to qualify for equity classification upon issuance. The total aggregate fair value of the Series H Placement Agent Warrants between the First Closing and the Second Closing of approximately $7,152 was included as a component of total transaction costs for the February 2026 Private Placement and was accordingly recorded in equity. The issuance date fair value of the Series H Placement Agent Warrants issued in the First Closing of $7,048 was determined using the Black Scholes Model using the following weighted average assumptions: the fair value of the Company’s common stock per share of $1.49; remaining term of 5 years; equity volatility of 101%; and a risk-free interest rate of 3.5%. The issuance date fair value of the Series H Placement Agent Warrants issued in the Second Closing of $104 was determined using the Black Scholes Model using the following weighted average assumptions: the fair value of the Company’s common stock per share of $1.37; remaining term of 5 years; equity volatility of 100%; and a risk-free interest rate of 3.6%.

Transaction costs totaling $10,216 were incurred related to the February 2026 Private Placement consisting of cash expenses for placement agent fees, legal fees, and accounting costs related to the financing, as well as the fair value of Series H Placement Agent Warrants. Net proceeds from the February 2026 Private Placement totaled $28,269. As the Series H Preferred Stock and Series H Warrants were classified in permanent equity, all transaction costs were recorded as an offset to additional paid-in capital.

February 2026 Omnibus Agreement

On February 24, 2026, the Company entered into the Omnibus Agreement, by and between the Company and January 2025 Investors, pursuant to which, the Company agreed to (i) repurchase from the January 2025 Investors $3,468 of aggregate principal amount of the Notes, representing the entire outstanding principal amounts of the Notes and any accrued and unpaid interest thereon, (ii) redeem 196 shares of Series G Preferred Stock held by the January 2025 Investors with an aggregate Stated Value of $196 and $27 of accrued and unpaid dividends thereon, representing all outstanding shares of Series G Preferred Stock, and (iii) redeem all Amended and Restated Warrants held by the January 2025 Investors, representing all outstanding Series A Warrants and Series B Warrants, for an aggregate cash purchase price of $9,000 (collectively, the “Repurchase”). The Repurchase closed on March 2, 2026.

On March 4, 2026, the Company filed a Certificate of Elimination (the “Certificate of Elimination”) with respect to its Series G Preferred Stock, with the Delaware Secretary of State. The Certificate of Elimination (i) eliminates the previous designation of 4,000 shares of Series G Preferred Stock, none of which were outstanding at the time of filing, (ii) causes such shares of Series G Preferred Stock to resume the status of authorized but unissued shares of preferred stock of the Company and (iii) eliminates all reference to the Series G Preferred Stock from the Company’s Amended and Restated Certificate of Incorporation, as amended.

Table of Contents

The Company allocated the total cash purchase price related to the Repurchase among the Series G Preferred Stock, the Notes, and the Amended and Restated Warrants using the relative fair value method on March 2, 2026 as summarized in the table below and accounted for each instrument in accordance with the relevant accounting guidance:


			Percentage of	Allocated consideration based
Instrument		Fair Value	total fair value	on relative fair value
Series G Preferred	$	398	1.57%	141
Notes		12,906	50.92%	4,582
Amended and Restated Warrants		12,044	47.51%	4,277
Total	$	25,348	100.00%	9,000

Accounting Treatment – Redemption of Series G Preferred Stock

The following table summarizes the calculation of the net carrying value of the Series G Preferred Shares before the Repurchase:


Stated value of outstanding Preferred Shares	$	196
Premium		27
Fair value of bifurcated derivative liability		22
Accrued Series G Convertible Preferred payable		2
	$	247

During the three months ended March 31, 2026 prior to the Repurchase the Company incurred $82 in dividends, and paid $76 of dividends in cash related to the Series G Preferred Stock. Additionally, the Company issued 1,855,442 shares of its common stock in conversion of Series G Preferred Shares for a total value of $543.

The Company estimated the $398 fair value of the remaining Series G Preferred Stock and the $22 fair value of the bifurcated embedded derivative related to the Series G Preferred Stock prior to the Repurchase on March 2, 2026 using a Monte Carlo simulation model, with the following inputs: the fair value of the Company’s common stock of $1.70 on the valuation date, estimated equity volatility of 148%, the time to maturity of 0.87 years, a discounted market interest rate 6.3%, a risk-free rate of 3.51%, dividend rate of 8.0%, a penalty dividend rate of 15.0%, and probability of default of 3.9%. Prior to the Repurchase, the Company recognized a gain of $40 related to the change in the fair value of the derivative during the three months ended March 31, 2026, which is recorded in other income (expense) on the unaudited condensed consolidated statement of operations.

The Company treated the extinguishment of the Series G Convertible Preferred Stock as a redemption in accordance with ASC Topic 260, Earnings Per Share. Accordingly, the Company thus recognized a total of $106 representing the difference between the allocated consideration of $141 and the carrying amount of the Series G Preferred Shares of $247 as a deemed contribution, which is added to net loss attributable to common stockholders in the unaudited consolidated statement of operations and comprehensive loss for the three months ended March 31, 2026 and recognized as additional paid-in capital.

Accounting Treatment – Extinguishment of the Notes

The following table summarizes the calculation of the net carrying value of the Notes before the Repurchase:


Outstanding principal	$	3,387
Unamortized premium		210
Accrued interest payable		81
Fair value of bifurcated derivative liability		9,431
	$	13,109

Table of Contents

The Company recognized interest expense totaling approximately $53 during the three months ended March 31, 2026 prior to the Repurchase, reflecting an effective interest rate of 8.80% and which was comprised of approximately $46 interest at the stated rate, and approximately $7 representing the amortization of the premium recognized at issuance.

The Company estimated the $12,906 fair value of the Notes and the $9,431 fair value of the bifurcated embedded derivative related to the Notes prior to the Repurchase on March 2, 2026 using a Monte Carlo simulation model, with the following inputs: the fair value of the Company’s common stock of $1.70 on the valuation date, estimated equity volatility of 108%, the time to maturity of 3.03 years, a discounted market interest rate of 6.5%, a risk-free rate of 3.43%, and probability of default of 15.6%. Prior to the Repurchase, the Company recognized a loss of $5,624 related to the change in the fair value of the derivative during the three months ended March 31, 2026, which is recorded in other income (expense) on the unaudited condensed consolidated statement of operations.

The Company accounted for the repurchase of the Notes as a debt extinguishment in accordance with ASC Topic 470, Debt. Accordingly, the $8,527 difference between the allocated consideration of $4,583 and the carrying amount of the Notes of $13,109 was recognized as a capital contribution recognized in additional paid-in capital as the Notes were held by certain of the Company’s investors.

Accounting Treatment – Repurchase of the Amended and Restated Warrants

The Company estimated the $12,044 fair value of the Amended and Restated Warrants prior to the Repurchase on March 2, 2026 using the Black Scholes Model using the following weighted average assumptions: the fair value of the Company’s common stock per share of $1.70; remaining term of 3.87 years; equity volatility of 103%; and a risk-free interest rate of 3.49%.

The Company accounted for the repurchase of the Amended and Restated Warrants in accordance with the guidance in ASC Topic 815, Derivatives and Hedging, related to the repurchase of freestanding equity-classified instruments. Accordingly, the allocated consideration of $4,277 was recorded as reduction of additional paid-in capital.

The following table represents the activity related to the Company’s warrants during the three months ended March 31, 2026:


				Weighted average			Remaining
		No. of Warrants		exercise price			contractual term (years)
December 31, 2025		9,045,000		$	1.00			4.18
Granted		71,999,234		$	0.35			—
Repurchased		(9,045,000)		$	1.00			—
March 31, 2026		71,999,234		$	0.35			3.06

All outstanding warrants were exercisable as of March 31, 2026 with an intrinsic value of $57,959.

Note 10. Stock-based Compensation

Total stock-based compensation for the three months ended March 31, 2026 and 2025 was $886 and $83, respectively. All stock-based compensation for the three months ended March 31, 2026 and 2025 is presented on the unaudited condensed consolidated statements of operations and comprehensive loss within general and administrative expense.

Table of Contents

The following tables summarize information about stock options and RSU activity for the three months ended March 31, 2026:


		RSUs				Stock options
				Weighted				Weighted				Weighted
				average				average			average
		No. of		grant date		No. of		exercise			remaining
		RSUs		fair value		options		price			term
Outstanding as of December 31, 2025		55,000		$	1.30	921,267		$	4.24			8.63 years
Granted		500,000			1.49	—			—
Exercised/Vested		(517,500)			1.47	—			—
Forfeited		—			—	—			—
Expired		—			—	(16,253)			—
Outstanding as of March 31, 2026		37,500		$	1.43	905,014		$	4.24			8.49 years
Exercisable as of March 31, 2026		—				763,588		$	4.83			8.37 years

Unrecognized stock-based payment cost related to non-vested stock options as of March 31, 2026 was $80, vesting over the next .17 years.

Unrecognized stock-based payment cost related to non-vested RSUs as of March 31, 2026 was $43.

Note 11. Revenue

Disaggregation of Revenue

The following table provides information about disaggregated revenue from contracts with customers by the nature of products and services provided:


		Three months ended
		March 31,
		2026			2025
Revenue, point in time		$	4,721		$	4,846
Revenue, over time			1,917			2,177
Total Revenue		$	6,638		$	7,023

As of March 31, 2026, the unrecognized committed amount of the Ginkgo/Bioworks contract is $362.

Contract Costs

The Company has no contract costs related to the periods presented.

Table of Contents

Contract Liabilities

Contract liabilities are classified as deferred revenue in the unaudited condensed consolidated balance sheets. The activity in deferred revenue as of March 31, 2026 and December 31, 2025, was as follows:


		March 31, 2026			December 31, 2025
Beginning of the period contract liability		$	1,126		$	1,143
Revenue recognized from the contract liabilities included in the beginning balance			(431)			(709)
Increases due cash received net of amounts recognized revenue during the period			95			692
End of period contract liability		$	790		$	1,126

Of the $1,126 outstanding as of December 31, 2025, $431 has been recognized as revenue for the three months ended March 31, 2026.

The Company has elected not to include in unfulfilled performance obligations for contracts in which the amount of revenue it recognizes is equal to the amount which the Company has a right to invoice. No revenue was recognized in the reporting period from performance obligations satisfied in previous periods. The Company applies the right-to-invoice practical expedient for its Priority Pass revenue stream and recognizes revenue in the amount it is entitled to invoice when that amount corresponds directly with the value of the performance to date. For the Company’s XpresTest business unit, there are no portions of unfulfilled performance obligations, because the Company’s efforts towards satisfying each of the performance obligations are expended evenly throughout the period of performance. Naples Wax Center offers prepaid wax packages that are either unlimited for one year or a set number of services. When the packages are purchased, the sales are recorded as deferred revenue, which was $790 and $837 as of March 31, 2026 and December 31, 2025, respectively. As services related to prepaid packages are used, revenue is recognized as income.

Note 12. Segment Information

The CODM evaluates performance and allocates resources for all of its reportable segments based on segment revenues and operating income.

The CODM uses segment revenues and segment operating income, to allocate resources (including employees, property, and financial or capital resources) for each segment predominantly in the annual budget and forecasting process. The CODM considers budget-to-actual variances on a monthly basis using the segment revenues and segment operating income when making decisions about allocating capital and personnel to the segments. The CODM also uses the segment revenues and operating income to assess the performance for each segment by comparing the results and return on assets of each segment with one another and in the compensation of certain employees. Expenses that can be specifically identified with a segment have been included as deductions in determining operating income. The Company separately presents the costs associated with certain corporate functions as Corporate and Other, primarily consisting of unallocated operating expenses including costs that were not specific to a particular segment but are general to the group, expenses incurred for insurance, legal fees, public company administrative costs, and other similar corporate expenses.

Table of Contents

The table below presents information about reported segments for the three and three months ended March 31, 2026 and 2025:


		Three months ended March 31, 2026
		XpresSpa			XpresTest			Naples Wax			Corporate and other			Total
Revenue		$	4,197		$	1,917		$	524		$	—		$	6,638
Operating (loss)/income		$	(592)		$	1,067		$	48		$	(5,937)		$	(5,414)


		Three months ended March 31, 2025
		XpresSpa			XpresTest			Naples Wax			Corporate and other			Total
Revenue		$	4,294		$	2,177		$	552		$	—		$	7,023
Operating (loss)/income		$	800		$	618		$	(422)		$	(4,154)		$	(3,158)

Table of Contents

A reconciliation of total segment revenues to total unaudited condensed consolidated revenue and of total segment operating (loss) income to total consolidated (loss) income, for the three and three months ended March 31, 2026 and 2025, is as follows:


		Three months ended March 31, 2026
		XpresSpa			XpresTest			Naples Wax			Corporate and other			Total
Revenue from external customers		$	4,197		$	1,917		$	524		$	—		$	6,638
Less: Significant Expenses (1):
Cost of Goods Sold - Labor			2,022			628			324			—			2,974
Cost of Goods Sold - Products & Services			263			—			6			—			269
Occupancy Cost			678			14			69			—			761
Other Cost of Revenue			179			34			68			—			281
Depreciation and amortization			150			—			6			16			172
Less: Other Segment Expenses (2):
Other segment operating expenses			1,497			174			3			5,921			7,595
Segment operating (loss) income		$	(592)		$	1,067		$	48		$	(5,937)		$	(5,414)



		Three months ended March 31, 2025
		XpresSpa			XpresTest			Naples Wax			Corporate and other			Total
Revenue from external customers		$	4,294		$	2,177		$	552		$	—		$	7,023
Less: Significant Expenses (1):
Cost of Goods Sold - Labor			2,356			1,289			322			—			3,967
Cost of Goods Sold - Products & Services			248			—			9			—			257
Occupancy Cost			976			6			152			—			1,134
Other Cost of Revenue			216			63			67			—			346
Depreciation and amortization			95			2			55			14			166
Less: Other Segment Expenses (2):
Other segment operating expenses			(397)			199			369			4,140			4,311
Segment operating (loss) income		$	800		$	618		$	(422)		$	(4,154)		$	(3,158)

(1)	The significant expense amounts align with the expenses that the CODM is regularly provided with to assess performance and allocate resources.

(2)	For all segments, SGA consists of the following:

Salaries & Benefits, Rent & Utilities, Office Supplies & Shipping, Travel & Entertainment, IT & Telecom, Repairs & Maintenance, Accounting, Legal, Franchise/Property Tax, Management/DBE Fees, Advertising & Marketing, Insurance

Table of Contents

Other Significant Items


		Three months ended March 31, 2026
		XpresSpa			XpresTest			Naples Wax			Corporate and other			Total
Stock based compensation		$	—		$	—		$	—		$	886		$	886


		Three months ended March 31, 2025
		XpresSpa			XpresTest			Naples Wax			Corporate and other			Total
Stock based compensation		$	37		$	3		$	—		$	43		$	83


		March 31, 2026
		XpresSpa			XpresTest			Naples Wax			Corporate and other			Total
Capital expenditures		$	228		$	3		$	4		$	4		$	239
Assets		$	20,508		$	1,458		$	1,028		$	1,998		$	24,992


		December 31, 2025
		XpresSpa			XpresTest			Naples Wax			Corporate and other			Total
Capital expenditures		$	1,780		$	—		$	932		$	147		$	2,859
Assets		$	6,884		$	1,291		$	1,013		$	2,029		$	11,217

The Company currently operates in two geographical regions: United States and all other countries, which include Netherlands, Turkey and United Arab Emirates. The following table represents the geographical revenue, and total long-lived asset information. There were no concentrations of geographical revenue and long-lived assets related to any single foreign country that were material to the Company’s unaudited condensed consolidated financial statements. Long-lived assets include property and equipment and right of use lease assets.


		Three months ended
		March 31,
		2026			2025
Revenue
United States		$	5,356		$	5,705
All other countries			1,282			1,318
Total revenue		$	6,638		$	7,023

Long-lived assets		March 31, 2026			December 31, 2025
United States		$	2,545		$	2,496
All other countries			182			208
Total long-lived assets		$	2,727		$	2,704

Table of Contents

Note 13. Net Loss per Share of Common Stock

The table below presents the computation of basic and diluted net loss per share of Common Stock:


		Three months ended
		March 31,
		2026			2025
Basic numerator:
Net loss attributable to XWELL, Inc.		$	(11,202)		$	(4,719)
Less: preferred stock dividends			(82)			(68)
Less: preferred stock accretion			—			(499)
Plus: deemed contribution on Repurchase of Series G Preferred Stock			106			—
Net loss attributable to common shareholders		$	(11,178)		$	(5,286)
Basic denominator:
Basic weighted average shares outstanding			7,396,148			5,261,024
Basic loss per share		$	(1.51)		$	(1.00)

Net loss per share data presented above excludes from the calculation of diluted net loss, the following potentially dilutive securities, having an anti-dilutive impact, in case of net loss
Both vested and unvested options to purchase an equal number of shares of Common Stock			905,014			516,096
Unvested RSUs to issue an equal number of shares of Common Stock			37,500			—
Warrants to purchase shares of Common Stock			71,999,234			5,347,594
Series G Convertible Preferred Stock on an as converted basis			—			2,933,452
Series H Convertible Preferred Stock on an as converted basis			66,665,957			—
Total number of potentially dilutive securities excluded from the calculation of loss per share attributable to common shareholders			139,607,705			8,797,142

In accordance with ASC 260, 552,500 RSUs that were fully vested on March 31, 2026 were included in basic and dilutive earnings per share as there were no remaining contingencies for these shares to be issued as of March 31, 2026.

Note 14. Related Party

On January 30, 2025, the Company entered into a consulting agreement (“Consulting Agreement”) with XWEL INV I, LLC (“XWEL INV I”) and Jason Aintabi (the “Consultant”) for the Consultant to provide advisory services to the Company. Mr. Aintabi serves as the Manager of XWEL INV I. The Consulting Agreement is deemed to be related party transaction as Mr. Aintabi is a greater than 5% beneficial owner of the Company’s securities. The Consulting Agreement was further extended on May 12, 2025 for a total period of twelve (12) months from the effective date of the agreement in exchange for a total amount for both the original and amended agreements of $530. On December 15, 2025 the Consulting Agreement was further amended to increase the value of agreement by $250, increasing the total amount for original and amended agreements to $780. On January 1, 2026, the Consulting Agreement was further extended for a period of three months from the effective date of the extension in exchange for an additional amount of $500. For the three months ended March 31, 2026, $562, of this contract was recognized in general and administrative expenses on the unaudited condensed consolidated statement of operations and comprehensive loss and $20 was recognized as a prepaid expense in other current assets on the unaudited condensed consolidated balance sheets as of March 31, 2026.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This Quarterly Report on Form 10-Q contains “forward-looking statements” that involve risks and uncertainties, as well as assumptions that, if they never materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The statements contained herein that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements are often identified by the use of words such as, but not limited to, “anticipates,” “believes,” “can,” “continues,” “could,” “estimates,” “expects,” “intends,” “may,” “will be,” “plans,” “projects,” “seeks,” “should,” “targets,” “will,” “would,” and similar expressions or variations intended to identify forward-looking statements. These statements are based on the beliefs and assumptions of our management based on information currently available to management. Such forward-looking statements are subject to risks, uncertainties and other important factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled “Risk Factors” included in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2026, as subsequently amended on April 30, 2026 (the “Annual Report”) and this Quarterly Report on Form 10-Q and any future reports we file with the SEC. The forward-looking statements set forth herein speak only as of the date of this report. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.

All references in this Quarterly Report on Form 10-Q to “we,” “us” and “our” refer to XWELL, Inc., a Delaware corporation, and its consolidated subsidiaries.

Overview

XWELL is a global wellness company operating multiple brands and focused on bringing restorative, regenerative and reinvigorating products and services to travelers. As of the date of this Quarterly Report on Form 10-Q, XWELL currently has three reportable operating segments: XpresSpa®, XpresTest®, and Naples Wax Center®

On October 25, 2022, the Company changed its name to XWELL, Inc. (“XWELL” or the “Company”) from XpresSpa Group, Inc. The Company’s common stock, par value $0.01 per share, which had previously been listed under the trading symbol “XSPA” on Nasdaq, now trades under the trading symbol “XWEL”. The Company filed an amended and restated certificate of incorporation with the Delaware Secretary of State on October 24, 2022 (as amended, the “Amended and Restated Certificate”) reflecting the name change. Rebranding to XWELL aligned the Company’s corporate strategy to build a pure-play wellness services company, in both the airport and off-airport marketplaces.

All amounts are in thousands, except share, per share, or as otherwise specifically noted.

XpresSpa

XWELL’s subsidiary, XpresSpa Holdings, LLC (“XpresSpa”) has been a global airport retailer of spa services through its XpresSpa spa locations, offering travelers premium spa services, including massage, nail and skin care, as well as spa and travel products.

As of March 31, 2026, there were 16 domestic XpresSpa locations in total. The Company also had nine international locations operating as of March 31, 2026, including two XpresSpa locations in the Dubai International Airport in the United Arab Emirates, one XpresSpa location in the Zayad International Airport in Abu Dhabi, United Arab Emirates, two XpresSpa locations in the Schiphol Amsterdam Airport in the Netherlands and four XpresSpa locations in the Istanbul Airport in Turkey.

Table of Contents

XpresTest

The Company, in partnership with certain COVID-19 testing partners, successfully launched its XpresCheck Wellness Centers, in June of 2020, through its XpresTest, Inc. subsidiary (“XpresTest”), which offered COVID-19 and other medical to the traveling public, as well as airline, airport and concessionaire employees, and TSA and U.S. Customs and Border Protection agents during the pandemic. As of December 31, 2023, the Company closed all XpresCheck locations and XpresTest no longer provides diagnostic testing services. XpresTest began conducting bio surveillance monitoring with the Centers for Disease Control and Prevention (CDC) in collaboration with Concentric by Ginkgo Bioworks Holdings, Inc. (“Ginkgo Bioworks”) in 2021.

The program was renewed through August 2024. The revenue to XpresTest from such one-year extension totaled approximately $7,044. In January 2024, the program funding and scope were expanded, a revenue increase of $4,000, to an estimated $11,044 in revenue for XpresTest with new collection locations at U.S. international airports and the roll out of multi-pathogen testing across the program. In July 2024, the contract was further amended to extend the time period for services by two weeks (extension period August 12, 2024 to August 25, 2024). An increase of $293 in revenue for the two week extension brought total revenue to $11,337. The program was again extended in August 2024 through February 25, 2025. The funding was expanded with a revenue increase of $3,763, to an estimated $15,100 in revenue for XpresTest. In February 2025, the program was extended through a three-year contract with a total base value of $22,200 over three years, and a maximum ceiling value of $24,800 within the same timeframe.

Naples Wax Center

XWELL’s subsidiary Naples Wax, LLC, d/b/a Naples Wax Centers (“Naples Wax Center” or “Naples Wax”) operates a group of upscale hair removal locations with core products and service offerings from face and body waxing to a range of skincare and cosmetic products. Naples Wax Center is intended to enable us to move beyond our airport client base with a business that can be adapted to a larger wellness platform while also growing our retail footprint to serve our long-term financial goals.

Although we recognize three segments of business, we believe there is opportunity to leverage a segment of our products and services across our platform of brands. Additionally, we are expanding our retail strategy, not only adding more products for sale but aligning those products more efficiently to our service offerings. This product strategy includes, for example, adding muscle relaxation patches to a neck or back massage to continue treatment after the delivery of the service.

We also plan to build our capability for delivering health and wellness services outside of the airport. We believe operating outside of the airport complements our offering and represents the fastest way to scale the XWELL family of brands.

We will be looking to further expand internationally. We believe a strategy for international expansion further advances our ability to expand our other brands including bio surveillance outside of the US.

Recent Developments

February 2026 Private Placement

Table of Contents

1,065,957 Series H Warrants issued on March 3, 2026 (the “Second Closing”, and collectively with the First Closing, the “Closing”).

In connection with the February 2026 Private Placement, pursuant to a placement agency agreement (the “Placement Agency Agreement”), dated as of February 24, 2026, by and between the Company and Dominari Securities LLC (the “Placement Agent”), the Company engaged the Placement Agent to act as an exclusive placement agent in connection with the February 2026 Private Placement and agreed to (i) pay to the Placement Agent (a) a cash fee equal to 8% of the gross proceeds of the February 2026 Private Placement and (b) reimbursements and payments of certain expenses, including non-accountable expense allowance equal to 1% of the gross proceeds raised in the February 2026 Private Placement and reasonable out-of-pocket expenses, not to exceed $250, and (ii) issue to the Placement Agent warrants (the “Placement Agent Warrants”) to purchase up to an aggregate number of shares of Common Stock equal to 8% of the aggregate number of shares of common stock underlying the securities issued in the February 2026 Private Placement, with terms identical to the Series H Warrants, except that the Series H Placement Agent Warrants have a term of five (5) years from the date of issuance. The Placement Agency Agreement contains customary representations, warranties and agreements of the parties, and customary indemnification obligations of the Company.

In connection with the February 2026 Private Placement, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the February 2026 Purchaser and the Placement Agent, pursuant to which the Company has agreed to prepare and file a registration statement with the SEC registering the resale of the shares of common stock underlying the Series H Preferred Stock and shares of common stock underlying the Series H Warrants and the Series H Placement Agent Warrants no later than the earlier of (a) 50 days after the later of (1) the closing date of the February 2026 Private Placement or (2) the Escrow Release Date (as defined in the Registration Rights Agreement) and (b) the second trading day following the date on which the Company files its Annual Report on Form 10-K for the year ended December 31, 2025 (the “Filing Deadline”), and to use best efforts to have the registration statement declared effective as promptly as practical thereafter, and in any event no later than 60 days following the Filing Deadline (or 90 days following the Filing Deadline in the event of a “full review” by the SEC). Such registration statement was filed on April 1, 2026, with the SEC and declared effective on April 15, 2026.

The Company used the net proceeds from the February 2026 Private Placement, in part, to repurchase certain outstanding indebtedness, redeem previously issued preferred equity and warrants in the Repurchase (see below February 2026 Omnibus Agreement).

February 2026 Omnibus Agreement

On February 24, 2026, the Company entered into the Omnibus Agreement, by and between the Company and January 2025 Investors, pursuant to which, the Company agreed to (i) repurchase from the January 2025 Investors $3,468 of aggregate principal amount of the Notes, representing the entire outstanding principal amounts of the Notes and any accrued and unpaid interest thereon, (ii) redeem 196 shares of Series G Preferred Stock held by the January 2025 Investors, with an aggregate Stated Value of $196 and $27 of accrued and unpaid dividends thereon, representing all outstanding shares of Series G Preferred Stock, and (iii) redeem all Amended and Restated Warrants held by the January 2025 Investors, representing all outstanding Series A Warrants and Series B Warrants, for an aggregate cash purchase price of $9,000 (collectively, the “Repurchase”). The Repurchase closed on March 2, 2026.

Series H Preferred Stock

The terms of the Series H Preferred Stock are set forth in the Series H Certificate of Designations. The shares of Series H Preferred Stock are convertible into the Conversion Shares at the election of the holders of the Series H Preferred Stock

Table of Contents

(the “Holders”) at any time at an initial conversion price of $0.47 per share (the “Conversion Price”). The Conversion Price is subject to customary adjustments for stock dividends, stock splits, reclassifications, stock combinations and the like.

Pursuant to the Series H Certificate of Designations, so long as any shares of the Series H Preferred Stock are outstanding, the Company may not, directly or indirectly, redeem, or declare or pay any cash dividend or distribution on, any securities of the Company without the prior express written consent of the Required Holders (as defined in the Certificate of Designations). In the event that dividends are consented to by the Required Holders, the Holders of the Series H Preferred Stock shall be entitled to receive dividends on shares of the Series H Preferred Stock equal (on an as-if-converted-to-Common-Stock basis) to and in the same form as dividends actually paid on shares of the Common Stock when, as and if such dividends are paid on shares of the Common Stock. No other dividends may be paid on shares of the Series H Preferred Stock.

There is no established public trading market for the Preferred Stock and the Company does not intend to list the Series H Preferred Stock on any national securities exchange or nationally recognized trading system.

Results of Operations

Revenue

We recognize revenue from the sale of XpresSpa and Naples Wax services when they are rendered at our stores and from the sale of products at the time goods are purchased at our stores or online (usually by credit card), net of discounts and applicable sales taxes.

During the third quarter of 2022, XpresTest, in partnership with Ginkgo Bioworks in continuation of their support to the CDC’s traveler-based SARS-CoV-2 genomic surveillance program was awarded a new contract. We recognize revenue over time for both sample collection performance obligations, using the input method based on time elapsed to measure progress towards satisfying each of the performance obligations. The Company recognizes revenue ratably (straight line basis) over the term of the contract.

Table of Contents

Cost of sales

Cost of sales for our XpresSpa, XpresTest, and Naples Wax segments consist of location and segment level costs. Location and segment level costs include all costs that are directly attributable to operations, primarily payroll and related benefit costs for personnel, occupancy costs and cost of products sold.

General and administrative expenses

General and administrative expenses include management and administrative personnel, overhead and occupancy costs, insurance, salaries, and various professional fees, as well as stock-based compensation for directors, management and administrative personnel.

Three months ended March 31, 2026, compared to the three months ended March 31, 2025

Revenue


		Three months ended March 31,
		2026			2025			Inc/(Dec)
Total revenue, net		$	6,638		$	7,023		$	(385)

The decrease in revenue of $385 or 5%, for the three months ended March 31, 2026, was primarily driven by the absence of revenues from the HyperPointe segment, which ceased operations as of December 31, 2025. Additionally, for XpresTest, specifically, there were additional revenues generated in three months ended March 31, 2025 from providing services to airports above the base contract amounts, which resulted in increased surge billing prices.

Cost of sales


		Three months ended March 31,
		2026			2025			Inc/(Dec)
Total cost of sales		$	4,285		$	5,704		$	(1,419)

The decrease in cost of sales of $1,419 or 25%, for the three months ended March 31, 2026, was primarily driven by the absence of costs associated with the HyperPointe segment, which ceased operations as of December 31, 2025. As a result, the Company experienced lower labor and related operating costs due to reduced sales activity and a smaller workforce compared to the prior period.

Depreciation and amortization


		Three months ended March 31,
		2026			2025			Inc/(Dec)
Depreciation and amortization		$	172		$	166		$	6

The increase in depreciation and amortization of approximately $6 or 4% for the three months ended March 31, 2026, was not individually significant and was primarily attributable to normal changes in the Company’s depreciable asset base compared to the three months ended March 31, 2025.

Table of Contents

General and administrative expenses


		Three months ended March 31,
		2026			2025			Inc/(Dec)
General and administrative		$	7,595		$	4,311		$	3,284

The increase of approximately 76% for the three months ended March 31, 2026, was primarily attributable to increased franchise tax expense, stock-based compensation related to shares granted and vested during the three months ended March 31, 2026, and higher consulting expenses, including amounts related to a related party consulting agreement (see Note 14), as well as higher legal and accounting fees. These increases were partially offset by a decrease in salaries and benefits expense compared to the three months ended March 31, 2025.

Other non-operating expenses


		Three months ended March 31,
		2026			2025			Inc/(Dec)
Foreign exchange gain (loss)		$	77		$	(455)		$	532
Other non-operating expense, net			(26)			(33)			7

The decrease in foreign exchange loss of $532 was primarily due to the fluctuation of the foreign exchange rate in Turkey, creating a remeasurement gain on our lease liability. The decrease in other non-operating expense of $7, net was primarily driven by a decrease in finance expenses related to bank fees and charges.

The following is a summary of the transactions included in other non-operating expense, net for the three months ended March 31, 2026 and 2025:


		Three months ended March 31,
		2026			2025
Bank fees and financing charges		$	(25)		$	(30)
Other			(1)			(3)
Total		$	(26)		$	(33)

Change in fair value of warrants and derivatives


		Three months ended March 31,
		2026			2025
Change in fair value of derivative liability		$	(5,584)		$	(142)
Change in fair value of warrant liability			—			2,590
Loss on issuance of Series G Preferred Stock			—			(3,443)

Table of Contents

The increase in the loss on change in fair value of derivative liability of $5,442 is primarily due to the issuance of convertible notes on November 10, 2025 which contained embedded features meeting the definition of a derivative and requiring bifurcation; the bifurcated derivative of these notes increased by $5,624 during the three months ended March 31, 2026 due to an increase in the Company’s stock price. The decrease in the change in fair value of warrant liability of $2,590 was due to the reclassification of the Company’s outstanding warrants from liability to equity in connection with the amendment on May 16, 2025; after reclassification, the warrants were no longer subject to remeasurement each reporting period with changes in fair value recognized in earnings, and thus no change in fair value of warrant liability was recorded for the three months ended March 31, 2026. The loss on issuance of Series G Preferred Stock during the three months ended March 31, 2025 was associated with the Securities Purchase Agreement dated as of January 14, 2025, by and between the Company and the investors named therein (the “January 2025 Purchase Agreement”); there was no such transaction or loss during the three months ended March 31, 2026.

Interest (expense) income, net


		Three months ended March 31,
		2026			2025			Inc/(Dec)
Interest (expense) income, net		$	(43)		$	58		$	(101)

The decrease of $101 for the three months ended March 31, 2026 was primarily driven by a reduction in interest income and the recognition of interest expense in the current period. In 2025, the Company earned approximately $51 of interest income on its Citi money market account, which has declined due to lower cash balances. In 2026, the Company incurred approximately $52 of interest expense related to a note payable.

Cash and Liquidity Analysis

As of March 31, 2026, the Company had cash and cash equivalents of $16,800 (excluding restricted cash), $7 in marketable securities, and total current assets of $19,747. The Company’s total current liabilities balance, which includes accounts payable, deferred revenue, accrued expenses, and operating lease liabilities was $8,389 as of March 31, 2026, and $12,892 as of December 31, 2025. The working capital surplus was $11,358 as of March 31, 2026, compared to a working capital deficit of $6,982 as of December 31, 2025.

The Company has taken actions to improve its overall cash position, right sizing its corporate structure and streamlining its operations, while at the same time the Company is aggressively trying to get the company to profitability. The Company continues to pursue strategic partnerships that the Company expects will further strengthen the long-term profitability of the business.

The increase in liquidity during the period was primarily attributable to proceeds from a private placement of Series H Convertible Preferred Stock with accompanying warrants completed in February 2026 (the “February 2026 Private Placement”), which generated net proceeds of $28,269. During the three months ended March 31, 2026, the Company used approximately $9,000 of these proceeds to repurchase outstanding Series G Preferred Stock, certain convertible notes, and related warrants as part of a strategic effort to simplify its capital structure and reduce future financing obligations. The remaining proceeds were used to support general corporate purposes and working capital needs.

As of the date of this Quarterly Report on Form 10-Q, the Company believes it has sufficient liquidity to fund its operations and meet its obligations for at least the next twelve months.

Critical Accounting Estimates

There have been no material changes to the Company’s critical accounting estimates from those disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.

Table of Contents

Known Trends, Events and Uncertainties

Ongoing conflicts in Russia and Ukraine, the Middle East, and Israel and Palestine, including related sanctions and countermeasures, are difficult to predict, and could adversely impact geopolitical and macroeconomic conditions, the global economy, and contribute to increased market volatility, which may in turn adversely affect our business and operations. We may not be able to raise sufficient additional capital and may tailor our business and operations based on the amount of funding we are able to raise in the future. Nevertheless, there is no assurance that these initiatives will be successful. Our ability to operate depends upon a large number of airplane travelers with the propensity for health and wellness, and in particular spa treatments and products, spending significant time post-security clearance check points at airports. The number of airline travelers at any given time is volatile and subject to change based on various conditions, including but not limited to market and other conditions, prices of travel fare, and oil and gas prices. Additionally, the US government shutdown, recent changes to U.S. policy implemented by the U.S. Congress, the Trump administration or any new administration have impacted and may in the future impact, among other things, the U.S. and global economy, tariffs, international trade relations, unemployment, immigration, healthcare, taxation, the U.S. regulatory environment, inflation and other areas. Although we cannot predict the impact, if any, of these changes to our business, they could adversely affect our business.

Other than as discussed above and elsewhere in this report, we are not aware of any trends, events or uncertainties that are likely to have a material effect on our financial condition.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

Not applicable.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) or Rule 15d-15(e) promulgated under the Exchange Act) that are designed to ensure that information required to be disclosed in Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer (Principal Financial and Accounting Officer), as appropriate, to allow timely decisions regarding required disclosure.

As of March 31, 2026, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. A “material weakness” is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim consolidated financial statements will not be prevented or detected on a timely basis. Based upon that evaluation, our management concluded that our disclosure controls and procedures were not effective as of March 31, 2026, due to the following material weaknesses:

The Company did not properly design, implement, and consistently operate effective controls over the completeness and accuracy of its accounting for leases under ASC 842.

The Company did not properly design or maintain effective entity level monitoring controls over the financial close and reporting process.

The Company did not design or maintain effective controls over its service organizations and IT vendors. More specifically, the Company did not have controls in place to review the applicable complementary user entity controls described in the service organizations’ reports for their potential impact on the Company’s financial reporting.

Table of Contents

The Company did not design, implement, and consistently operate effective controls over the revenue process. The Company’s controls surrounding the revenue reports and reconciliations were not designed and did not operate at a level of precision that would prevent or detect a material misstatement.

5)The Company did not design, implement, and consistently operate effective controls over its’ foreign subsidiaries.

This type of evaluation is performed on a quarterly basis so that conclusions of management, including our Chief Executive Officer and the Chief Financial Officer, concerning the effectiveness of the disclosure controls can be reported in our periodic reports on Form 10-Q and Form 10-K. The overall goals of these evaluation activities are to monitor our disclosure controls and to modify them as necessary. We intend to maintain the disclosure controls as dynamic systems that we adjust as circumstances merit. Based on the foregoing, our Chief Executive Officer and the Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of March 31, 2026.

Remediation Plan for Material Weakness in Internal Control over Financial Reporting

Management is committed to the remediation of the Company’s material weaknesses, as well as the continued improvement of the Company’s internal control over financial reporting. Management has implemented, and continues to implement, the actions described below to remediate the underlying causes of the control deficiencies that gave rise to the material weaknesses. Until the remediation efforts described below, including any additional measures management identifies as necessary, are completed, the material weaknesses described above will continue to exist. We cannot provide any assurance that the below remediation efforts will be successful or that our internal control over financial reporting will be effective as a result of these efforts. Management has commenced the following actions and will continue to assess additional opportunities for remediation on an ongoing basis:

The Company has turned on the multi-currency features related to its cloud-based accounting systems.

The Company has engaged outside service providers to assist with the valuation, accounting, and recording of key reporting areas such as leases, revenue recognition and stock compensation expense.

The Company has contracted an independent consulting firm to assist with the preparation of the Financial Statements and U.S. GAAP accounting research.

The Company has engaged outside service providers to review the applicable complementary user entity controls described in the service organizations’ reports for their potential impact on the Company’s financial reporting.

Changes in Internal Control over Financial Reporting

Other than as set forth in the foregoing paragraph, there have been no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the three months ended March 31, 2026 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II – OTHER INFORMATION

Item 1. Legal Proceedings.

From time to time, we may be involved in certain claims and litigation arising out of the ordinary course and conduct of business. Management assesses such claims and, if it considers that it is probable that an asset had been impaired or a liability had been incurred and the amount of loss can be reasonably estimated, provisions for loss are made based on management’s assessment of the most likely outcome.

The information set forth in Note 8 Commitments and Contingencies of the Notes to unaudited condensed consolidated financial statements of this Quarterly Report on Form 10-Q is incorporated by reference herein.

There are no other material proceedings in which any of our directors, officers, affiliates, any registered or beneficial stockholder of more than 5% of our common stock, or any associate of any of the foregoing is an adverse party or has a material interest adverse to our interest.

Item 1A. Risk Factors.

Investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described in Part I, Item 1A under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, in addition to the other information included in this Quarterly Report on Form 10-Q before making an investment decision regarding our common stock. If any of these risks actually occur, our business, financial condition, or operating results would likely suffer, possibly materially, the trading price of our common stock could decline, and you could lose part or all of your investment.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

There were no unregistered sales of equity securities during the quarter ended March 31, 2026, other than as reported in our Current Reports on Form 8-K filed with the SEC.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information

None.

Table of Contents

Item 6. Exhibits.


Exhibit No.		Description

3.1		Certificate of Designations of Series H Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on March 4, 2026).

3.2		Certificate of Elimination of Series G Convertible Preferred Stock (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed with the SEC on March 4, 2026).

4.1		Form of Warrant (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed with the SEC on February 25, 2026).

4.2		Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.2 to the Company’s Current Report on Form 8-K filed with the SEC on February 25, 2026).

10.1		Securities Purchase Agreement, dated February 24, 2026, by and among the Company and the investor signatory thereto (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on February 25, 2026).

10.2		Form of Registration Rights Agreement (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the SEC on February 25, 2026).

10.3		Placement Agency Agreement, dated February 24, 2026, by and between the Company and Dominari Securities LLC (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K filed with the SEC on February 25, 2026).

10.4		Form of Lock-Up Agreement (incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K filed with the SEC on February 25, 2026).

10.5		Omnibus Agreement, dated February 24, 2026, by and among the Company and the investors signatory thereto (incorporated by reference to Exhibit 10.5 to the Company’s Current Report on Form 8-K filed with the SEC on February 25, 2026).

31.1*		Certification of Principal Executive Officer pursuant to Exchange Act, Rules 13a – 14(a) and 15d – 14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2*		Certification of Principal Financial Officer pursuant to Exchange Act, Rules 13a – 14(a) and 15d – 14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32**		Certifications of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS*		Inline XBRL Instance Document

101.SCH*		Inline XBRL Taxonomy Extension Schema Document

101.CAL*		Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF*		Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB*		Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE*		Inline XBRL Taxonomy Extension Presentation Linkbase Document

104*		Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

*		Filed herewith.
**		Furnished herein.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		XWELL, Inc.


Date:	May 20, 2026	By:	/s/ Ezra T. Ernst
			Ezra T. Ernst
			Chief Executive Officer
			(Principal Executive Officer)


Date:	May 20, 2026	By:	/s/ Ian Brown
			Ian Brown
			Chief Financial Officer
			(Principal Financial and Accounting Officer)

Source: View Original Filing on SEC EDGAR

FAQ

How did XWEL’s revenue change in the quarter ended March 31, 2026?

XWEL’s revenue for the quarter was $6,638 thousand, down slightly from $7,023 thousand a year earlier. The decline reflects lower contributions from certain operations, including the absence of HyperPointe revenues and reduced surge billing in the XpresTest segment.

How much cash and working capital did XWEL have as of March 31, 2026?

As of March 31, 2026, XWEL held $16,800 thousand in cash and cash equivalents and $7 thousand in marketable securities. Total current assets were $19,747 thousand and current liabilities were $8,389 thousand, producing a working capital surplus of $11,358 thousand.

What are the key terms of XWEL’s February 2026 Series H Preferred Stock financing?

In February 2026, XWEL issued 31,333 shares of Series H Convertible Preferred Stock at $1,000 stated value each, initially convertible into up to 66,665,957 common shares at $0.47 per share, plus Series H warrants for 66,665,957 shares at a $0.345 exercise price.

How did XWEL use proceeds from the February 2026 private placement?

The February 2026 private placement generated net proceeds of $28,269 thousand. XWEL used approximately $9,000 thousand to repurchase outstanding Series G preferred stock, related convertible notes, and warrants, with the remaining funds applied to general corporate purposes and working capital needs.

Does XWEL believe it can continue as a going concern after Q1 2026?

The company prepared its financial statements on a going concern basis and states that, based on current cash and expected operating cash flows, it believes it has sufficient liquidity to fund operations and meet obligations for at least the next twelve months following the report date.

What segments contribute to XWEL’s revenue and operating results?

XWEL operates three reportable segments: XpresSpa, XpresTest, and Naples Wax Center. For Q1 2026, segment operating income (loss) was $(592) thousand for XpresSpa, $1,067 thousand for XpresTest, $48 thousand for Naples Wax, and $(5,937) thousand for Corporate and other.

XWELL (XWEL) boosts liquidity with Series H financing despite wider Q1 2026 loss

Rhea-AI Filing Summary

Positive

Negative

Insights

Key Figures

Key Terms

FAQ

How did XWEL’s revenue change in the quarter ended March 31, 2026?

How much cash and working capital did XWEL have as of March 31, 2026?

What are the key terms of XWEL’s February 2026 Series H Preferred Stock financing?

How did XWEL use proceeds from the February 2026 private placement?

Does XWEL believe it can continue as a going concern after Q1 2026?

What segments contribute to XWEL’s revenue and operating results?

XWELL (XWEL) boosts liquidity with Series H financing despite wider Q1 2026 loss

Rhea-AI Filing Summary

Positive

Negative

Insights

Equity & credit structure analyst neutral

Key Figures

Key Terms

FAQ

How did XWEL’s revenue change in the quarter ended March 31, 2026?

What was XWEL’s net loss and loss per share for Q1 2026?

How much cash and working capital did XWEL have as of March 31, 2026?

What are the key terms of XWEL’s February 2026 Series H Preferred Stock financing?

How did XWEL use proceeds from the February 2026 private placement?

Does XWEL believe it can continue as a going concern after Q1 2026?

What segments contribute to XWEL’s revenue and operating results?